mercoledì, 29 marzo 2023
13 Febbraio 2019

Dasatinib Approved in EU for Pediatric Ph+ ALL

February 11, 2019 – The European Commission has approved dasatinib in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), according to Bristol-Myers Squibb, the manufacturer of the TKI. The approval, which includes dasatinib in both tablet form and powder for oral suspension formulation, is based on findings from the multicenter, historically … (leggi tutto)